Stay updated on DTG/3TC in HIV-1 Adolescents Clinical Trial
Sign up to get notified when there's something new on the DTG/3TC in HIV-1 Adolescents Clinical Trial page.

Latest updates to the DTG/3TC in HIV-1 Adolescents Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with a revision update from v2.16.0 to v2.16.1.SummaryDifference0.7%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check63 days agoChange DetectedThe webpage has undergone significant updates, including the introduction of a new study on the efficacy and safety of a fixed-dose combination of Dolutegravir and Lamivudine (DTG/3TC) for HIV-infected adolescents, while extensive details about previous regimens and study phases have been removed.SummaryDifference26%
Stay in the know with updates to DTG/3TC in HIV-1 Adolescents Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DTG/3TC in HIV-1 Adolescents Clinical Trial page.